ClinicalTrials.gg
Active, not recruitingNCT06710847SYLVERUpdated Feb 2, 2026

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

A Phase 1/2 interventional study of GSK4418959 and PD-1 inhibitor in Neoplasms, Colorectal, Solid Tumor and Colon Cancer, sponsored by GlaxoSmithKline. Active, not recruiting at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Colorectal Neoplasms by GlaxoSmithKline — 3 open to participants now, 6 under way, none of them phase 3. Colorectal Neoplasms · GlaxoSmithKline.

Enrollment
12th of 14
14 · median 82
Started
2024
the only one that year
Phase 1/2
4 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Colorectal Neoplasms by GlaxoSmithKline, this one is the 12th largest by enrollment, is the only one that started in 2024, is one of 4 in phase 1/2, and was the 11th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 14 studies in Colorectal Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.

03

Conditions studied

  • Neoplasms, Colorectal
  • Solid Tumor
  • Colon Cancer
  • Rectal Cancer
  • Endometrial Cancer

Keywords

  • GSK4418959
  • DNA Helicase Werner Inhibitor (WRNi)
  • PD-1 inhibitor
  • Solid tumors
  • Colon cancer
  • Rectal cancer
  • Colorectal cancer
  • Endometrial cancer
  • Mismatch repair deficient
  • dMMR
  • microsatellite instability high
  • MSI-H
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Parts 1, 2, and 3 inclusion criteria:

  • Has a diagnosed advanced (unresectable, or recurrent) solid tumor
  • Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) status at the time of Pre-screening and MMR/MSI status will be determined by central reference laboratory
  • Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample
  • Intends to receive GSK4418959 (alone or in combination with inhibitor, as determined between Investigator and sponsor) as next
  • Has an (ECOG) performance status of 0-2
  • Is expected to have a minimum of 3 months
  • Has adequate organ function, as defined in the protocol

Parts 1 and 3 inclusion criteria:

  • Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options

Part 2 inclusion criteria:

  • Has histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)
  • Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease including at least one line of Immune checkpoint inhibitors (ICI) therapy
  • Has (i.e., at least 1 target lesion) during the Screening period per 1.1, as determined by the investigator

Exclusion criteria

Exclusion Criteria:

Parts 1, 2, and 3 exclusion criteria:

  • Has not recovered (i.e., to Grade ≤1 or to baseline) from prior anticancer therapy-induced AEs
  • Has received prior treatment with a WRN inhibitor
  • Is unable to swallow and retain orally administered study treatment
  • Has symptomatic uncontrolled brain or
  • Has a known additional that progressed or required active treatment within the last 2 years because reoccurrence of another malignancy would confound interpretation by 1.1 criteria. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer that is considered to be low risk for progression by the investigator
  • Has any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs
  • Has severe liver fibrosis
  • Has cirrhosis or current unstable liver or biliary disease
  • Has known to any of the study interventions or any of their
  • Has known WRN syndrome
  • Has an active disease that has required systemic treatment in the past 2 years

Part 3 exclusion criteria:

  • Has experienced any of the following with prior immunotherapy: any immune mediated adverse events (imAE) of Grade ≥3, immune-related severe neurologic events of any grade, exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug rash with eosinophilia and systemic signs syndrome [DRESS] syndrome), or myocarditis of any grade. Non- laboratory abnormalities are not exclusionary
  • Has any history of interstitial lung disease or pneumonitis
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Part 1: Dose escalation of GSK4418959 monotherapy

    Participants will receive GSK4418959 as monotherapy.

    Drug: GSK4418959

  • Experimental
    Part 2: Dose expansion of GSK4418959 monotherapy

    Participants will receive GSK4418959 as monotherapy.

    Drug: GSK4418959

  • Experimental
    Part 3: Dose escalation of GSK4418959 plus PD-1 inhibitor

    Participants will receive GSK4418959 plus PD-1 inhibitor.

    Drug: GSK4418959 · Biological: PD-1 inhibitor

Interventions

  • DrugGSK4418959

    GSK4418959 will be administered.

  • BiologicalPD-1 inhibitor

    PD-1 inhibitor will be administered.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with dose limiting toxicities (DLTs) during DLT observation period

    Time frame: Up to 21 days

  2. Part 3: Number of participants with dose limiting toxicities (DLTs) during DLT observation period

    Time frame: Up to 21 days

  3. Part 1: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation period

    Time frame: Up to 21 days

  4. Part 3: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation period

    Time frame: Up to 21 days

  5. Part 1: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation period

    Time frame: Up to 21 days

  6. Part 3: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation period

    Time frame: Up to 21 days

  7. Part 2: Objective Response Rate (ORR)

    ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by investigator assessment.

    Time frame: Up to approximately 26 months

Secondary outcomes

  1. Part 1: Area under the concentration-time curve (AUC) for GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

  2. Part 1: Maximum concentration (Cmax) for GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

  3. Part 1: Time to maximum concentration (Tmax) for GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

  4. Part 3: AUC for GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

  5. Part 3: Cmax for GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

  6. Part 3: Tmax for GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

  7. Part 1: Number of participants with TEAEs

    Time frame: Up to approximately 42 months

  8. Part 2: Number of participants with TEAEs

    Time frame: Up to approximately 42 months

  9. Part 3: Number of participants with TEAEs

    Time frame: Up to approximately 42 months

  10. Part 1: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs

    Time frame: Up to approximately 42 months

  11. Part 2: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs

    Time frame: Up to approximately 42 months

  12. Part 3: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs

    Time frame: Up to approximately 42 months

  13. Part 1: Number of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 42 months

  14. Part 2: Number of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 42 months

  15. Part 3: Number of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 42 months

  16. Part 2: Progression-free Survival (PFS)

    PFS is defined as time from first dose to progressive disease (as assessed per RECIST 1.1 by Investigator assessment) or death from any cause, whichever is earlier.

    Time frame: Up to approximately 42 months

  17. Part 2: Duration of Response (DoR)

    DoR is defined as time from first documented PR or CR to progressive disease (as assessed per RECIST 1.1 by investigator assessment) or death from any cause, whichever is earlier for participants who have achieved a confirmed CR or PR.

    Time frame: Up to approximately 42 months

  18. Part 2: Plasma concentration of GSK4418959

    Time frame: From first day of dosing for the duration of treatment until end of interventional phase (EOI) (up to approximately 42 months)

07

Study locations

22 sites
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Denver, Colorado 80218, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Melbourne, Victoria 3000, Australia
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Shizuoka, 411-8777, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Tokyo, 135-8550, Japan
  • GSK Investigational Site
    Amsterdam, 1066 CX, Netherlands
  • GSK Investigational Site
    Daegu, 41404, South Korea
  • GSK Investigational Site
    Gyeonggi-do, 10408, South Korea
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Barcelona, 08023, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2026, 18 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 18 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Nov 29, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Jun 22, 2026
CompletionEst.
Jun 22, 2026
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710847
Lead sponsor
GlaxoSmithKline
Collaborators
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Dec 13, 2024
Primary completion
Jun 22, 2026 (estimated)
Completion
Jun 22, 2026 (estimated)
Last update
Feb 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion